tiletamine hydrochloride has been researched along with B-Cell Chronic Lymphocytic Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benkisser-Petersen, M; Bleckmann, D; Burger, M; Claus, R; Decker, S; Dierks, C; Duyster, J; Foerster, K; Saleem, S; Simon-Gabriel, CP; Thornton, N; Umezawa, K; Veelken, H; Zirlik, K | 1 |
| Higashihara, M; Horie, R; Motoji, T; Okamura, T; Shoda, M; Taira, M; Umezawa, K; Utsunomiya, A; Watanabe, M; Watanabe, T | 1 |
2 other study(ies) available for tiletamine hydrochloride and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biomarkers; Cell Line, Tumor; Cell Survival; Coculture Techniques; Cyclohexanones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mesenchymal Stem Cells; NF-kappa B; RNA, Small Interfering; Signal Transduction; Tumor Microenvironment | 2018 |
DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Benzamides; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; CD40 Antigens; Cell Line, Tumor; Cell Survival; Cyclohexanones; Down-Regulation; Drug Synergism; Female; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Minor Histocompatibility Antigens; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine | 2006 |